Science & Enterprise subscription

Follow us on Twitter

  • See our infographic on Saturday ... https://t.co/915iuVjrta https://t.co/foiMp01PXB
    about 2 hours ago
  • Results from a clinical trial show a drug approved for a rare lymph node disease can stabilize or improve the condi… https://t.co/E66q37t6Ey
    about 9 hours ago
  • New post on Science and Enterprise: Trial Shows Rare Disease Drug Treats Covid-19 Patients https://t.co/nq3C3i5IwP #Science #Business
    about 9 hours ago
  • NY Times ... Covid-19 Changed How the World Does Science, Together https://t.co/a2GEMqNlgg
    about 18 hours ago
  • A smartphone app is collecting individual reports about Covid-19 symptoms and other health conditions to provide ea… https://t.co/gxdMGhThvO
    about 1 day ago

Please share Science & Enterprise

PhRMA: 88 HIV/AIDS Meds in Development at U.S. Companies

AIDS ribbon (geneva.usmission.gov)

(geneva.usmission.gov)

A report by Pharmaceutical Research and Manufacturers of America (PhRMA) says U.S. biopharmaceutical companies are testing 88 medicines and vaccines to treat or prevent HIV/AIDS and related conditions. The report, issued on World AIDS Day (1 December 2011), also lists 36 currently approved medications for HIV infection and AIDS.

According to PhRMA’s report, more than half (49 of 88 or 56%) of the medications in development are antivirals, with another 27 drugs classified as vaccines. The remaining 12 medicines are cell or gene therapies, immunomodulators, and others treating related disorders (e.g. AIDS-associated neuropathy). All of the 88 drugs listed are either in clinical trials or awaiting FDA review.

In a statement, the International AIDS Vaccine Initiative (IAVI) says the global rate of new infections has stabilized at 2.7 million new infections a year for the past five years. IAVI attributes this stabilization to HIV control strategies including condoms, male circumcision, prevention of mother-to-child HIV transmission, harm reduction for people who use drugs, and a decrease in transmission from people living with HIV who are on treatment.

The group notes that antiretroviral treatments have been available since 1996, and are now more tolerable and a lot easier to take, although less than half of the people who need these treatments have access to them. “Fortunately,” says IAVI, “there have been extraordinary advances in HIV science, including significant progress toward the development of preventive vaccines and microbicides, the use of antiretroviral treatments as prophylaxis, and even a functional cure.”

Read more:

*     *     *

Please share Science & Enterprise ...

1 comment to PhRMA: 88 HIV/AIDS Meds in Development at U.S. Companies